0001209191-18-008165.txt : 20180207
0001209191-18-008165.hdr.sgml : 20180207
20180207171717
ACCESSION NUMBER: 0001209191-18-008165
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180206
FILED AS OF DATE: 20180207
DATE AS OF CHANGE: 20180207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Conner Edward R.
CENTRAL INDEX KEY: 0001691265
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 18581955
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD.
STREET 2: POINT RICHMOND TECH CENTER
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-06
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001691265
Conner Edward R.
C/O SANGAMO THERAPEUTICS, INC.
POINT RICHMOND TECH CTR, 501 CANAL BLVD.
RICHMOND
CA
94804
0
1
0
0
Sr. VP & Chief Medical Officer
Common Stock
2018-02-06
4
M
0
5000
3.20
A
13125
D
Common Stock
2018-02-06
4
S
0
5000
18.4871
D
8125
D
Stock Option (Right to Buy)
3.20
2018-02-06
4
M
0
5000
0.00
D
2026-11-29
Common Stock
5000
185000
D
Includes 6,125 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date.
All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2017.
The price reported is a weighted average price. The shares were sold at prices ranging from $18.05 to $18.80 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
/s/ Denise Winn, Attorney-in-Fact
2018-02-07